Benchmark analyst Mike Hickey raised the firm’s price target on Marcus to $20 from $18 and keeps a Buy rating on the shares. The firm, which is raising estimates for Marcus’ Q3 performance driven by a significantly stronger-than-expected domestic box office, now projects 3.5% growth in box office admissions for the company’s fiscal quarter, “far surpassing” its previous forecast of an 8% decline, the analyst tells investors.